Triad: Industrializing medicinal chemistry

Combinatorial chemistry has not been the panacea for lead compound design that its inventors hoped, as it has turned out that quantity doesn't necessarily equal quality. But that doesn't mean that the search for better lead generation technologies should stop, as the coming deluge of targets would overwhelm conventional medicinal chemistry.

Triad Therapeutics Inc.'s response to the problem is structure-based drug design, using its Integrated Object-Oriented PharmacoEngineering (IOPE) technology to construct focused combinatorial libraries of small molecule inhibitors that are specific for selected gene

Read the full 830 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE